医学系

Keyphrases

1. Japan 100%
2. Tumor 41%
3. Confidence Interval 28%
4. Schizophrenia 23%
5. Hepatocellular Carcinoma 23%
6. Magnetic Resonance Imaging 21%
7. Moyamoya Disease 21%
8. Older Men 20%
9. Risk Factors 20%
10. Japanese Patients 19%
11. Chemotherapy 19%
12. Apoptosis 18%
13. Computed Tomography 17%
14. Odds Ratio 16%
15. Older Women 16%
16. After Surgery 16%
17. Type 2 Diabetes Mellitus (T2DM) 15%
18. Pancreatic Cancer 15%
19. Clinical Outcomes 15%
20. Ultrasound 15%
21. Overall Survival 14%
22. Monkey 14%
23. Liver 14%
24. Induced Apoptosis 13%
25. Multivariate Analysis 13%
26. Environment Studies 13%
27. Child Study 13%
28. Childrens 13%
29. Gastric Cancer 13%
30. Gene Expression 12%
31. T Cells 12%
32. Hippocampus 12%
33. Knock-in Mouse Model 12%
34. Lung 12%
35. Left Ventricular Assist Device 11%
36. No Significant Difference 11%
37. Platelet-derived Growth factor-BB (PDGF-BB) 11%
38. N-methyl-D-aspartate Receptor (NMDAR) 11%
39. Japanese Population 11%
40. Insulin Resistance 11%
41. Carbon Ion Radiotherapy 10%
42. Human Mesenchymal Stem Cells (hMSCs) 10%
43. Hazard Ratio 10%
44. Tumor Necrosis Factor-α 10%
45. Clinical Features 10%
46. Resection 10%
47. Elderly Patients 10%
48. Mouse Model 10%
49. Adverse Events 10%
50. Insulin 10%
51. Overexpression 10%
52. Prognostic Factors 10%
53. Global Burden of Disease Study 9%
54. Phosphorylation 9%
55. Transcatheter Aortic Valve Replacement 9%
56. Aneurysm 9%
57. Metastasis 9%
58. Inflammation 9%
59. Hyperthermia 9%
60. During Pregnancy 9%
61. Ulcerative Colitis 9%
62. Amygdala 8%
63. Heart Failure 8%
64. Schizophrenic Patients 8%
65. Patients with Schizophrenia 8%
66. Ca2+ 8%
67. Tumor Cells 8%
68. Type 1 Diabetes Mellitus (T1DM) 8%
69. Central Nervous System 8%
70. Poor Prognosis 8%
71. Macrophages 8%
72. Quantitative PCR 8%
73. Surgical Treatment 8%
74. Single-photon Emission Computed Tomography (SPECT) 8%
75. Patients with Heart Failure 8%
76. Oral Tongue Squamous Cell Carcinoma (OTSCC) 8%
77. Obesity 8%
78. Pancreas 8%
79. Ossification of the Posterior Longitudinal Ligament 8%
80. Lung Cancer 8%
81. Interleukin-6 7%
82. Quality of Life 7%
83. Molecular Mechanism 7%
84. Platelet-derived Growth Factor Receptor (PDGFR) 7%
85. Young Males 7%
86. Pancreaticoduodenectomy 7%
87. Mitogen-activated Protein Kinase 7%
88. Clinical Characteristics 7%
89. Heart Rate 7%
90. Body Mass Index 7%
91. University Hospital 7%
92. Randomized Controlled Trial 7%
93. B Cells 7%
94. High Risk 7%
95. Healthy Controls 7%
96. Cisplatin 7%
97. Lymph Node Metastasis 7%
98. Transgenic Mice 7%
99. Surgical Outcomes 7%
100. Spinal Cord 7%

Medicine and Dentistry

1. Neoplasm 65%
2. Disease 41%
3. Surgery 38%
4. Congestive Heart Failure 25%
5. Recurrent Disease 25%
6. Magnetic Resonance Imaging 24%
7. Hepatocellular Carcinoma 24%
8. Chemotherapy 22%
9. Malignant Neoplasm 21%
10. Computer Assisted Tomography 20%
11. Overall Survival 19%
12. Left Ventricular Assist Device 18%
13. Pancreas Cancer 18%
14. Hemodynamic 17%
15. Metastatic Carcinoma 17%
16. Percutaneous Aortic Valve Replacement 16%
17. Adverse Event 16%
18. Bleeding 14%
19. Odds Ratio 14%
20. Retrospective Study 14%
21. Abdominal Cancer 13%
22. Injury 13%
23. Diagnosis 13%
24. Aneurysm 13%
25. Moyamoya Disease 13%
26. Global Disease Burden 12%
27. Infection 12%
28. Prevalence 12%
29. Multivariate Analysis 12%
30. Lung 12%
31. Apoplexy 11%
32. Prognostic Factor 11%
33. Cohort Analysis 11%
34. Lung Cancer 11%
35. In Vitro 11%
36. Artery 10%
37. Biopsy Technique 10%
38. Radiation Therapy 10%
39. Hazard Ratio 10%
40. Survival Rate 10%
41. Ion Therapy 9%
42. Programmed Cell Death 9%
43. Cancer Cell 9%
44. Hepatectomy 9%
45. Endoscopic Ultrasound 9%
46. Messenger RNA 9%
47. Ossification 9%
48. Lymphocyte 9%
49. Adenocarcinoma 9%
50. Randomized Controlled Trial 9%
51. Lymph Node Metastasis 9%
52. Elderly Patient 8%
53. Cancer 8%
54. Diabetes Mellitus 8%
55. Surgical Anastomosis 8%
56. Prostate Cancer 8%
57. Brain Ischemia 8%
58. Maturity Onset Diabetes of the Young 8%
59. Pediatrics 8%
60. Pancreaticoduodenectomy 7%
61. Posterior Longitudinal Ligament 7%
62. Diabetes 7%
63. Neck 7%
64. Combination Therapy 7%
65. Immunohistochemistry 7%
66. Biological Marker 7%
67. Clear Cell Renal Cell Carcinoma 7%
68. Kampo 7%
69. Cholestasis 7%
70. Quality of Life 7%
71. Surgeon 7%
72. Stenosis 7%
73. Postoperative Complication 7%
74. Carcinoma 7%
75. Clinical Feature 6%
76. Atrial Fibrillation 6%
77. Single-Photon Emission Computed Tomography 6%
78. Revascularization 6%
79. Carotid Artery Stenosis 6%
80. Body Mass Index 6%
81. Clinical Trial 6%
82. Mouth Squamous Cell Carcinoma 6%
83. Morphology 6%
84. Liver Metastasis 6%
85. Internal Carotid Artery 6%
86. Lymph Node 6%
87. Drug Therapy 6%
88. Non Small Cell Lung Cancer 6%
89. Progression Free Survival 6%
90. Prospective Study 6%
91. Ulcerative Colitis 6%
92. Squamous Cell Carcinoma 6%
93. Pancreas Adenocarcinoma 6%
94. Lenvatinib 5%
95. Tumor Cell 5%
96. Laminoplasty 5%
97. Transitional Cell Carcinoma 5%
98. Middle Cerebral Artery 5%
99. B Cell 5%
100. Bone Marrow Stromal Cell 5%